AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-13 (canceled).

Claim 14. (previously presented): Method of the administration of drugs with binding affinity for plasma protein, which is characterized in that, in the administration of a first drug with binding affinity for plasma protein, a single or plural second drug with binding affinity for the same plasma protein for which the first drug has binding affinity, is administered simultaneously with the first drug or before or after the administration of the first drug to thereby regulate the binding of the first drug to the plasma protein.

Claim 15. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 14, wherein the second drug has binding affinity to the same binding sites on plasma protein to which the first drug has binding affinity.

Claim 16. (previously presented): The method of the administration of drug with binding affinity for plasma protein according to Claim 14, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

Claim 17. (currently amended): The method of the administration of drugs with binding affinity for plasma protein according to Claim 15, wherein the first drug is a ~~raiodiagnostic~~radiodiagnostic drug for in vivo use or ~~the~~ a radiotherapeutic drug for in vivo use.

Claim 18. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu) , 67-gallium (^{67}Ga), 81m-krypton (^{81m}Kr)~~(^{81}Kr)~~, 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-rhenium (^{186}Re), 188-rhenium (^{188}Re), 201-thallium ($^{201}T1$), 212-bismuth (^{212}Bi), 213-bismuth (^{213}Bi) and 211-astatine (^{211}At).

Claim 19. (currently amended): The method of the administration of drugs with binding affinity for plasma protein according to Claim 16 or 17, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol ~~or its derivatives~~compound, a monaminomonoamidobisthiol ~~or its derivatives~~compound, a bisamidobisthiol ~~or its derivatives~~compound, a mercaptoacetylglycylglycylglycine ~~or its derivatives~~compound, a hexamethylpropyleneamineoxime ~~or its derivatives~~compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] ~~or its derivatives~~compound, a 2,3-dimercaptosuccinic acid ~~or its derivatives~~compound, an ethylenecysteine dimer ~~derivatives~~compound, a methoxyisobutylisonitrile ~~derivatives~~compound, a polyamine ~~derivatives~~compound, a pyriodoxylydeneaminate ~~derivatives~~compound, methylene diphosphonate, a hydroxymethylene diphosphonate ~~derivatives~~compound, a ß-methyl-ω-phenylpentadecanoic acid ~~or its~~

~~derivatives~~compound, N-isopropylamphetamine, hippuric acid, ~~and~~ benzylguanidine and a tropane ~~derivatives~~compound.

Claim 20. (previously presented): The method of the administration of drugs with binding affinity for plasma protein according to any one of claims 14 to 17, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, cefatriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-6-naphthyl acetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

Claim 21. (previously presented): A pharmaceutical preparation for regulating binding affinity of a first drug for plasma protein, which comprises a first drug with binding affinity for plasma protein and a single or plural second drug with binding affinity for the same plasma protein, for which the first drug has binding affinity.

Claim 22. (currently amended): The pharmaceutical preparation according to Claim 21, wherein each of the first drug and the second drug is ~~separately filled~~ in a separate container, and prepared as a kit ~~form for supply~~.

Claim 23. (previously presented): The pharmaceutical preparation according to Claim 21, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

Claim 24. (previously presented): The pharmaceutical preparation according to Claim 22, wherein the second drug has binding affinity to the same binding sites on the plasma protein, to which the first drug has binding affinity.

Claim 25. (previously presented): The pharmaceutical preparation according to any one of Claims 21 to 24, wherein the first drug is a radiodiagnostic drug for in vivo use or a radiotherapeutic drug for in vivo use.

Claim 26. (previously presented): The pharmaceutical preparation according to Claim 25, wherein the radiodiagnostic drug for in vivo use or the radiotherapeutic drug for in vivo use is radiolabeled with one nuclide selected from the group consisting of 11-carbon (^{11}C), 15-oxygen (^{15}O), 18-fluorine (^{18}F), 32-phosphorus (^{32}P), 59-iron (^{59}Fe), 67-copper (^{67}Cu), 67-gallium (^{67}Ga), 81m-krypton (^{81m}Kr), 81-rubidium (^{81}Rb), 89-strontium (^{89}Sr), 90-yttrium (^{90}Y), 99m-technetium (^{99m}Tc), 111-indium (^{111}In), 123-iodine (^{123}I), 125-iodine (^{125}I), 131-iodine (^{131}I), 133-xenon (^{133}Xe), 117m-tin (^{117m}Sn), 153-samarium (^{153}Sm), 186-rhenium (^{186} Re), 188-rhenium (^{188}Re), 201-thallium (^{201}Tl), 212-bismuth (^{212}Bi), 213-bismuth (^{213}Bi) and 211-astatine (^{211}At).

Claim 27. (currently amended): The pharmaceutical preparation according to Claim 25, wherein the first drug has one group labeled with nuclide and the group is selected from the group consisting of a bisaminothiol ~~or its derivatives~~compound, a monaminomonoamidobisthiol ~~or its derivatives~~compound, a bisamidobisthiol ~~or its derivatives~~compound, a mercaptoacetylglycylglycylglycine ~~or its derivatives~~compound, a hexamethylpropyleneamineoxime ~~or its derivatives~~compound, an ethylenebis [bis(2-ethoxyethyl) phosphine] ~~or its derivatives~~compound, a 2,3-dimercaptosuccinic acid ~~or its derivatives~~compound, an ethylenecysteine dimer ~~derivatives~~compound, a methoxyisobutylisonitrile ~~derivatives~~compound, a polyamine ~~derivatives~~compound, a

pyriodoxylydeneaminate ~~derivatives~~compound, methylene diphosphonate, a hydroxymethylene diphosphonate ~~derivatives~~compound, a ß-methyl-ω-phenylpentadecanoic acid ~~or its derivatives~~compound, N-isopropylamphetamine, hippuric acid, benzylguanidine and a tropane ~~derivatives~~compound..

Claim 28. (previously presented): The pharmaceutical preparation according to any one of Claims 21 to 24, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazolin, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.

Claim 29. (previously presented): The pharmaceutical preparation according to Claim 25, wherein the single or plural second drug is selected from the group consisting of bucolome, cefazoline, etoposide, phenylbutazone, aspirine, salicylic acid, ceftriaxone, sulfamethizole, valproic acid, nabumetone, 6-methoxy-2-naphthylacetic acid, ibuprofen, probenecid, dansyl-L-asparagine, verapamil and disopyramide.